History
2019.07 University of Dundee partners with Bukwang Pharmaceutical Company to tackle new drug treatment
for Parkinson’s disease
2019.06 Bukwang Announced commencement of Phase 2 Clinical Study of JM-010 in major European countries
2018.12 Bukwang Announces completion of dosing of MLR-1023’s phase 2b study.
2018.06 Acquired ISO45001 (Occupational Health and Safety Management System) certification for the first time in the
Korean pharmaceutical industry
2018.04 Bukwang initiates phase 3 study with lurasidone HCl for patients with Schizophrenia
2018.01 Bukwang Pharmaceutical Co., Ltd.(“Bukwang”) registered patents on a therapeutic candidate for Levodopa-
induced dyskinesia in Parkinson’s disease. - International application and registration of patents on therapeutic
use and composition, formulations and metabolites for Levodopa-induced dyskinesia in Parkinson’s disease.
2017.08 MLR-1023, a novel candidate for type 2 diabetes, was selected by the KHIDI(Korea Health Industry Development
Institute) under the Ministry of Health and Welfare as a project to support the development of advanced medical
technology.
2017.05 Bukwang Pharmaceutical Co., Ltd. acquired the exclusive right to distribute the domestic co-marketing rights of
"200 units of Meditoxin", therapeutic botulinum toxin injectable from Eisaikorea.
2017.04 Bukwang Pharmaceutical Co., Ltd. announces the conclusion of an exclusive license agreement with Sumitomo
Dainippon Pharma on lurasidone HCI for Korea
2017.02 Bukwang Pharmaceutical Co., Ltd. submitted Phase 2b IND for new diabetic drug candidate, MLR-1023.
2017.01 Bukwang Pharmaceutical Co., ‘JM-010’, a treatment of dyskinesia in Parkinson's Disease patients, is approved for
Orphan Drug Designation from Korea MFDS.
2016.06 Dyna Therapeutics Co., Ltd, a newly launched project focused company by Bukwang, is granted worldwide
exclusive option to license SOL-804.
2016.11 Factory received certificate of The Occupational Health and Safety Management System (OHSAS18001) /
The Environmental Management System (ISO14001) by Korean Foundation for Quality (IQNet partner).
2016.03 Signs an export agreement with Kalbe International Pte. Ltd. for Dexid Tab.,
an incrementally modified drug for diabetic neuropathy, in 6 countries in South East Asia
2015.07 Invests in Acer Therapeutics, a US bio-venture company specialized in rare disease treatments
2015.06 Bukwang Medica, an OTC-specialized subsidiary company, is established with the aim of strengthening
and diversifying the OTC business
2015.05 Invests in a bio/health industry fund established by Medivate Partners
2015.04 Bukwang’s subsidiary Contera Pharma ApS receives an approval of “JM-010” phase IIa IND
from South African authority for the treatment of LID (Levodopa-Induced Dyskinesia)
2014.12 Signs a license agreement with Contera Pharma ApS on JM-010, acquiring rights for relevant patented
technology about treatment of Levodopa-Induced Dyskinesia (LID)
2014.12 Receives award from the Ministry of Science, ICT and Future Planning for contribution
to the Open Source Software World Challenge 2014
2014.11 Acquires a CNS-specialist bio venture company, Contera Pharma ApS, located in Copenhagen, Denmark
2014.09 Korea MFDS (Ministry of Food and Drug Safety) approves phase II IND for the new anti-diabetic agent,
MLR-1023, which is currently co-developed by both Melior (US) and Bukwang (Korea).
2014.09 Levovir® (clevudine) capsules are first exported to Thailand
2014.07 Receives an award from the Financial Supervisory Service at The Best Audit Award
2014.05 Establishes subsidiary company Bukwang C&C, specialized in ERP system and services
2013.11 Receives marketing approval from Korea Ministry of Food and Drug Safety (MFDS)
for incrementally modified drug “Dexid Tab” to treat diabetic neuropathy
2013.11 Signs a global partnership agreement with TVM Captial, a life science venture capital company in Canada,
as a strategic collaboration partner
2012.11 Invests in EyeGene, a Korean bio-venture company
2011.12 IND for phase 1/2a clinical trial of apatinib mesylate in the US is approved by the US FDA
2011.04 The main R&D center is newly built next to the main offices in Daebang-dong, Seoul (current location)
2010.01 Levovir® (clevudine) is first exported to the Philippines
2009.01 Signs an agreement with LSK BioPartners. Inc. (US), about Apatinib mesylate, acquiring rights for relevant patents
and technology in Korea, Japan and Europe
2008.08 The second factory receives approval as a cGMP facility
2008.03 Receives Order of Industrial Service Merit Tin Tower on Taxpayer Day
2007.02 Levovir® (clevudine) capsules are launched in Korea
2007.02 Levovir® (clevudine) capsules are awarded the Grand Prize for the 8th Korea New Drug Awards
2006.11 Nominated as one of the “200 Best Under a Billion” by Forbes
2006.11 Clevudine (Levovir® capsules) receives marketing approval from the Korean FDA for treatment of type B hepatitis
2004.11 Signs an agreement with Eisai (Japan), about transfer of relevant patents and technology for clevudine
2000.05 Changes company name to “Bukwang Pharmaceutical Company Limited”
2000.03 Invests in a bio-venture firm Anterogen Co., Ltd.
1989.12 The second factory is built in Ansan, Korea
1988.08 Bukwang launches IPO
1985.04 Becomes the first in Korea to receive approval for KGMP implementation
in manufacture of pharmaceutical products
1962.03 Changes company name to “Bukwang Pharmaceutical Ind, Co., Ltd.”
1960.10 Bukwang is established as “Bukwang Trading Company”
1998.02 Signs an agreement with Triangle, based in the US, for technology transfer and marketing
rights of clevudine
1997.01 Selected as Company with Excellent Labor-Management Relationship
1996.04 Signs an agreement with University of Georgia and Yale University, for co-development
and marketing rights of L-FMAU
1993.12 The main Research and Development center is built